FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316664536> ?p ?o ?g. }

• W4316664536 abstract "Abstract Background Radioguided surgery (RGS) has recently emerged as a valuable new tool in the management of recurrent prostate cancer (PCa). After preoperative injection of a 99m Tc-labeled prostate-specific membrane antigen (PSMA) inhibitor, radioguided intraoperative identification and resection of lesions is facilitated by means of suitable γ-probes. First clinical experiences show the feasibility of RGS and suggest superiority over conventional lymph node dissection in recurrent PCa. However, commonly used [ 99m Tc]Tc-PSMA-I&S exhibits slow whole-body clearance, thus hampering optimal tumor-to-background ratios (TBR) during surgery. We therefore aimed to develop novel 99m Tc-labeled, PSMA-targeted radioligands with optimized pharmacokinetic profile to increase TBR at the time of surgery. Methods Three 99m Tc-labeled N4-PSMA ligands were preclinically evaluated and compared to [ 99m Tc]Tc-PSMA-I&S. PSMA affinity (IC 50 ) and internalization were determined on LNCaP cells. Lipophilicity was assessed by means of the distribution coefficient log D 7.4 and an ultrafiltration method was used to determine binding to human plasma proteins. Biodistribution studies and static µ SPECT/CT-imaging were performed at 6 h p.i. on LNCaP tumor-bearing CB17-SCID mice. Results The novel N4-PSMA tracers were readily labeled with [ 99m Tc]TcO 4 − with RCP > 95%. Comparable and high PSMA affinity was observed for all [ 99m Tc]Tc-N4-PSMA-ligands. The ligands showed variable binding to human plasma and medium to low lipophilicity (log D 7.4 − 2.6 to − 3.4), both consistently decreased compared to [ 99m Tc]Tc-PSMA-I&S. Biodistribution studies revealed comparable tumor uptake among all [ 99m Tc]Tc-N4-PSMA-ligands and [ 99m Tc]Tc-PSMA-I&S, while clearance from most organs was superior for the novel tracers. Accordingly, increased TBR were achieved. [ 99m Tc]Tc-N4-PSMA-12 showed higher TBR than [ 99m Tc]Tc-PSMA-I&S for blood and all evaluated tissue. In addition, a procedure suitable for routine clinical production of [ 99m Tc]Tc-N4-PSMA-12 was established. Labeling with 553 ± 187 MBq was achieved with RCP of 98.5 ± 0.6% ( n = 10). Conclusion High tumor accumulation and favorable clearance from blood and non-target tissue make [ 99m Tc]Tc-N4-PSMA-12 an attractive tracer for RGS, possibly superior to currently established [ 99m Tc]Tc-PSMA-I&S. Its GMP-production according to a method presented here and first clinical investigations with this novel radioligand is highly recommended." @default.
• W4316664536 created "2023-01-17" @default.
• W4316664536 creator A5034376855 @default.
• W4316664536 creator A5035923943 @default.
• W4316664536 creator A5051959238 @default.
• W4316664536 creator A5059272171 @default.
• W4316664536 creator A5075644184 @default.
• W4316664536 creator A5081600729 @default.
• W4316664536 creator A5091020946 @default.
• W4316664536 date "2023-01-16" @default.
• W4316664536 modified "2023-10-14" @default.
• W4316664536 title "Synthesis and preclinical evaluation of novel 99mTc-labeled PSMA ligands for radioguided surgery of prostate cancer" @default.
• W4316664536 cites W2030940240 @default.
• W4316664536 cites W2120398128 @default.
• W4316664536 cites W2134019417 @default.
• W4316664536 cites W2155847415 @default.
• W4316664536 cites W2175340293 @default.
• W4316664536 cites W2175765437 @default.
• W4316664536 cites W2463848034 @default.
• W4316664536 cites W2468071338 @default.
• W4316664536 cites W2520541785 @default.
• W4316664536 cites W2604258833 @default.
• W4316664536 cites W2664930764 @default.
• W4316664536 cites W2767261848 @default.
• W4316664536 cites W2786988345 @default.
• W4316664536 cites W2793368694 @default.
• W4316664536 cites W2795899442 @default.
• W4316664536 cites W2887123205 @default.
• W4316664536 cites W2887389533 @default.
• W4316664536 cites W2890462791 @default.
• W4316664536 cites W2894608759 @default.
• W4316664536 cites W2937485616 @default.
• W4316664536 cites W2971373538 @default.
• W4316664536 cites W2984918942 @default.
• W4316664536 cites W2990351859 @default.
• W4316664536 cites W2996117498 @default.
• W4316664536 cites W3005893761 @default.
• W4316664536 cites W3011518560 @default.
• W4316664536 cites W3021114717 @default.
• W4316664536 cites W3087151197 @default.
• W4316664536 cites W3109709228 @default.
• W4316664536 cites W3112041870 @default.
• W4316664536 cites W3116313352 @default.
• W4316664536 cites W3135722323 @default.
• W4316664536 cites W3137575514 @default.
• W4316664536 cites W3145096632 @default.
• W4316664536 cites W3191561331 @default.
• W4316664536 cites W4210272297 @default.
• W4316664536 cites W4220772037 @default.
• W4316664536 cites W4285388513 @default.
• W4316664536 doi "https://doi.org/10.1186/s13550-022-00942-7" @default.
• W4316664536 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36645586" @default.
• W4316664536 hasPublicationYear "2023" @default.
• W4316664536 type Work @default.
• W4316664536 citedByCount "1" @default.
• W4316664536 countsByYear W43166645362023 @default.
• W4316664536 crossrefType "journal-article" @default.
• W4316664536 hasAuthorship W4316664536A5034376855 @default.
• W4316664536 hasAuthorship W4316664536A5035923943 @default.
• W4316664536 hasAuthorship W4316664536A5051959238 @default.
• W4316664536 hasAuthorship W4316664536A5059272171 @default.
• W4316664536 hasAuthorship W4316664536A5075644184 @default.
• W4316664536 hasAuthorship W4316664536A5081600729 @default.
• W4316664536 hasAuthorship W4316664536A5091020946 @default.
• W4316664536 hasBestOaLocation W43166645361 @default.
• W4316664536 hasConcept C112705442 @default.
• W4316664536 hasConcept C121608353 @default.
• W4316664536 hasConcept C126322002 @default.
• W4316664536 hasConcept C142724271 @default.
• W4316664536 hasConcept C150903083 @default.
• W4316664536 hasConcept C178790620 @default.
• W4316664536 hasConcept C185592680 @default.
• W4316664536 hasConcept C201399114 @default.
• W4316664536 hasConcept C20417620 @default.
• W4316664536 hasConcept C207001950 @default.
• W4316664536 hasConcept C2777807558 @default.
• W4316664536 hasConcept C2779720271 @default.
• W4316664536 hasConcept C2779723316 @default.
• W4316664536 hasConcept C2780192828 @default.
• W4316664536 hasConcept C2780849966 @default.
• W4316664536 hasConcept C2989005 @default.
• W4316664536 hasConcept C502942594 @default.
• W4316664536 hasConcept C71924100 @default.
• W4316664536 hasConcept C86803240 @default.
• W4316664536 hasConceptScore W4316664536C112705442 @default.
• W4316664536 hasConceptScore W4316664536C121608353 @default.
• W4316664536 hasConceptScore W4316664536C126322002 @default.
• W4316664536 hasConceptScore W4316664536C142724271 @default.
• W4316664536 hasConceptScore W4316664536C150903083 @default.
• W4316664536 hasConceptScore W4316664536C178790620 @default.
• W4316664536 hasConceptScore W4316664536C185592680 @default.
• W4316664536 hasConceptScore W4316664536C201399114 @default.
• W4316664536 hasConceptScore W4316664536C20417620 @default.
• W4316664536 hasConceptScore W4316664536C207001950 @default.
• W4316664536 hasConceptScore W4316664536C2777807558 @default.
• W4316664536 hasConceptScore W4316664536C2779720271 @default.
• W4316664536 hasConceptScore W4316664536C2779723316 @default.
• W4316664536 hasConceptScore W4316664536C2780192828 @default.
• W4316664536 hasConceptScore W4316664536C2780849966 @default.
• W4316664536 hasConceptScore W4316664536C2989005 @default.

• next